Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

Hisanori Hirokawa; Hirokuni Hirata; Hayase Azuma; Kei Sugitate; Sayo Soda; Jun Matsushima; Yasutsugu Fukushima

doi:10.1016/j.rmcr.2024.102094

Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

Respir Med Case Rep. 2024 Aug 22:51:102094. doi: 10.1016/j.rmcr.2024.102094. eCollection 2024.

Authors

Hisanori Hirokawa¹, Hirokuni Hirata¹, Hayase Azuma¹, Kei Sugitate¹, Sayo Soda², Jun Matsushima³, Yasutsugu Fukushima¹

Affiliations

¹ Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan.
² Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kitakobayashi, Shimotusga-gun, Tochigi, 321-0293, Japan.
³ Department of Pathology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan.

Abstract

There is no established treatment for lung adenocarcinoma with uncommon/compound epidermal growth factor receptor (EGFR) mutations. We report a case of a 73-year-old man with stage IVB lung adenocarcinoma harboring E709G and L861Q EGFR mutations. After 2 months of afatinib treatment, significant tumor shrinkage was observed, and the patient's condition remained stable for 1 year. This case highlights the potential effectiveness of afatinib for treating rare stage IV lung adenocarcinoma with these specific EGFR mutations.

Keywords: Case report; E709G; EGFR; L861Q; Lung adenocarcinoma; Uncommon/compound mutation; afatinib.

Publication types

Case Reports